Summary

This article presents primary results from The Stabilization of Plaques Using Darapladib-TIMI 52 trial [SOLID-TIMI 52; NCT01000727], demonstrating that darapladib is ineffective at reducing major coronary events when started within 30 days after an acute coronary syndrome (ACS) event.